Structural basis for driving HER2-addicted cancer cells into apoptosis
16 September 2013

Patients do already benefit from several anti-HER2 drugs like the monoclonal antibodies trastuzumab (Herceptin®) and pertuzumab (Perjeta®), which have been shown in vitro to act only as a cytostatic agent, but not as a cytotoxic agent.

New HER2-binders employing alternative mechanisms to abolish HER2-dependent signaling and causing cytotoxic effects could expand and complement existing anti-HER2 therapies.

Popular tags in SelectScience

Buying guides

Write a Review

Join the Global SelectScience Community Today! It’s FREE!

Helping you make informed decisions about the latest lab products and technologies:

  • Be the first to learn about new technologies
  • 10,000+ trusted product reviews from your peers
  • Compare 500,000 products and manufacturers
  • Get exclusive buying tips from experts
  • Find solutions fast: 10,000+ Application Notes, Webinars and Videos

Connect with 250,000 scientists... All in one place!

Become a member today!